Kancera AB (publ) (KAN.ST)
SEK 1.21
(0.5%)
SEK 1.21
(0.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 17.97 Million SEK | 30.03% |
| 2022 | 13.82 Million SEK | 27.19% |
| 2021 | 10.87 Million SEK | 0.47% |
| 2020 | 10.81 Million SEK | -59.83% |
| 2019 | 26.93 Million SEK | 121.21% |
| 2018 | 12.17 Million SEK | -2.7% |
| 2017 | 12.51 Million SEK | -7.35% |
| 2016 | 13.5 Million SEK | 146.21% |
| 2015 | 5.48 Million SEK | -39.92% |
| 2014 | 9.13 Million SEK | 36.43% |
| 2013 | 6.69 Million SEK | -49.18% |
| 2012 | 13.17 Million SEK | -4.82% |
| 2011 | 13.83 Million SEK | 370.04% |
| 2010 | 2.94 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 29.42 Million SEK | 63.67% |
| 2024 Q2 | 12.63 Million SEK | -57.05% |
| 2023 Q2 | 14.58 Million SEK | -4.81% |
| 2023 Q4 | 17.97 Million SEK | 47.35% |
| 2023 Q1 | 15.32 Million SEK | 10.81% |
| 2023 FY | 17.97 Million SEK | 30.03% |
| 2023 Q3 | 12.2 Million SEK | -16.34% |
| 2022 Q1 | 12.4 Million SEK | 14.12% |
| 2022 Q3 | 10.2 Million SEK | -26.26% |
| 2022 FY | 13.82 Million SEK | 27.19% |
| 2022 Q2 | 13.84 Million SEK | 11.59% |
| 2022 Q4 | 13.82 Million SEK | 35.44% |
| 2021 Q4 | 10.87 Million SEK | -13.37% |
| 2021 Q2 | 10.42 Million SEK | -5.78% |
| 2021 Q3 | 12.54 Million SEK | 20.35% |
| 2021 FY | 10.87 Million SEK | 0.47% |
| 2021 Q1 | 11.06 Million SEK | 2.26% |
| 2020 Q2 | 14.81 Million SEK | -52.5% |
| 2020 FY | 10.81 Million SEK | -59.83% |
| 2020 Q1 | 31.18 Million SEK | 15.78% |
| 2020 Q3 | 11.64 Million SEK | -21.39% |
| 2020 Q4 | 10.81 Million SEK | -7.09% |
| 2019 FY | 26.93 Million SEK | 121.21% |
| 2019 Q3 | 12.73 Million SEK | -25.39% |
| 2019 Q2 | 17.07 Million SEK | 0.13% |
| 2019 Q1 | 17.05 Million SEK | 40.03% |
| 2019 Q4 | 26.93 Million SEK | 111.45% |
| 2018 FY | 12.17 Million SEK | -2.7% |
| 2018 Q4 | 12.17 Million SEK | -8.66% |
| 2018 Q2 | 18.85 Million SEK | 30.94% |
| 2018 Q1 | 14.39 Million SEK | 15.06% |
| 2018 Q3 | 13.33 Million SEK | -29.29% |
| 2017 Q1 | 13.95 Million SEK | 3.33% |
| 2017 Q3 | 24.22 Million SEK | 51.44% |
| 2017 Q2 | 15.99 Million SEK | 14.6% |
| 2017 FY | 12.51 Million SEK | -7.35% |
| 2017 Q4 | 12.51 Million SEK | -48.34% |
| 2016 Q3 | 11.24 Million SEK | 0.52% |
| 2016 FY | 13.5 Million SEK | 146.21% |
| 2016 Q4 | 13.5 Million SEK | 20.14% |
| 2016 Q2 | 11.18 Million SEK | 51.64% |
| 2016 Q1 | 7.37 Million SEK | 34.45% |
| 2015 Q4 | 5.48 Million SEK | -42.9% |
| 2015 Q1 | 9.28 Million SEK | 1.7% |
| 2015 FY | 5.48 Million SEK | -39.92% |
| 2015 Q2 | 9.97 Million SEK | 7.46% |
| 2015 Q3 | 9.6 Million SEK | -3.73% |
| 2014 Q2 | 10 Million SEK | 16.94% |
| 2014 FY | 9.13 Million SEK | 36.43% |
| 2014 Q4 | 9.13 Million SEK | -4.07% |
| 2014 Q3 | 9.51 Million SEK | -4.91% |
| 2014 Q1 | 8.55 Million SEK | 27.88% |
| 2013 Q3 | 3.7 Million SEK | 8.55% |
| 2013 Q4 | 6.69 Million SEK | 80.45% |
| 2013 FY | 6.69 Million SEK | -49.18% |
| 2013 Q1 | 1.09 Million SEK | -91.7% |
| 2013 Q2 | 3.41 Million SEK | 212.63% |
| 2012 Q3 | 10.66 Million SEK | -19.72% |
| 2012 Q4 | 13.17 Million SEK | 23.52% |
| 2012 FY | 13.17 Million SEK | -4.82% |
| 2012 Q2 | 13.28 Million SEK | -1.64% |
| 2012 Q1 | 13.5 Million SEK | -2.42% |
| 2011 Q2 | 19.13 Million SEK | 32.18% |
| 2011 Q3 | 15.37 Million SEK | -19.64% |
| 2011 Q4 | 13.83 Million SEK | -10.01% |
| 2011 FY | 13.83 Million SEK | 370.04% |
| 2011 Q1 | 14.47 Million SEK | 391.71% |
| 2010 Q4 | 2.94 Million SEK | 1116.53% |
| 2010 FY | 2.94 Million SEK | 0.0% |
| 2010 Q3 | 242 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -92.67% |
| Amniotics AB (publ) | 10.54 Million SEK | -70.456% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -306.191% |
| BioArctic AB (publ) | 139.5 Million SEK | 87.113% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.852% |
| Saniona AB (publ) | 86.08 Million SEK | 79.116% |
| Simris Alg AB (publ) | 148.93 Million SEK | 87.929% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 56.0% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -368.421% |
| NextCell Pharma AB | 13.68 Million SEK | -31.331% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -30.544% |
| AcouSort AB (publ) | 10.37 Million SEK | -73.232% |
| Active Biotech AB (publ) | 13.4 Million SEK | -34.164% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 83.134% |
| Camurus AB (publ) | 414.81 Million SEK | 95.666% |
| Cantargia AB (publ) | 54.97 Million SEK | 67.295% |
| Genovis AB (publ.) | 98.04 Million SEK | 81.664% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 2.79% |
| Mendus AB (publ) | 51.22 Million SEK | 64.904% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -55.398% |
| LIDDS AB (publ) | 3.75 Million SEK | -378.647% |
| Lipum AB (publ) | 7.53 Million SEK | -138.498% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -248.546% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 85.499% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -662.103% |
| OncoZenge AB (publ) | 1.69 Million SEK | -958.152% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.271% |
| Xintela AB (publ) | 14.01 Million SEK | -28.277% |
| Ziccum AB (publ) | 6.38 Million SEK | -181.434% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 6.189% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 74.978% |
| CombiGene AB (publ) | 4.15 Million SEK | -332.58% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 74.721% |
| Intervacc AB (publ) | 21.68 Million SEK | 17.076% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 48.045% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 32.687% |
| Corline Biomedical AB | 6.78 Million SEK | -164.811% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 70.699% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -11.547% |
| Aptahem AB (publ) | 8.99 Million SEK | -99.804% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 61.07% |
| Fluicell AB (publ) | 8.91 Million SEK | -101.66% |
| Biovica International AB (publ) | 34.76 Million SEK | 48.29% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -54.08% |
| Abliva AB (publ) | 16.78 Million SEK | -7.133% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 91.623% |
| 2cureX AB (publ) | 2.93 Million SEK | -512.538% |
| I-Tech AB | 16.2 Million SEK | -10.941% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.484% |
| Cyxone AB (publ) | 4.69 Million SEK | -283.0% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -34.889% |
| Biosergen AB | 5.08 Million SEK | -253.55% |
| Nanologica AB (publ) | 79.32 Million SEK | 77.337% |
| SynAct Pharma AB | 51.83 Million SEK | 65.316% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -126.167% |
| BioInvent International AB (publ) | 90.45 Million SEK | 80.124% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -246.067% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 90.1% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -902.118% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -41.07% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -147.631% |